Clinical Trials Browser

Phase 2 × INDUSTRY × Adjuvants, Immunologic × Clear all

NCT01290692 2023-07-03

Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

Astrocytoma, Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma, Neoplasms, Nervous System Diseases, Nervous System Neoplasms, Central Nervous System Neoplasms